12:00 AM
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tivozanib: Additional Phase III data

Additional data from the open-label, international Phase III TIVO-1 trial in 517 patients showed that once-daily 1.5 mg oral tivozanib met the secondary endpoint of improving ORR vs. sorafenib (33% vs. 23%, p=0.014). In a subgroup of patients who had previously received systemic therapy, tivozanib led to a median PFS of 11.9 months vs. 9.1 months for sorafenib. OS data, which are not yet...

Read the full 298 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >